Celularity (NASDAQ:CELU) Stock Price Up 2.4% – Time to Buy?

Celularity, Inc. (NASDAQ:CELU) shares rose 2.4% during mid-day trading on Wednesday . The stock traded as high as $0.8468 and last traded at $0.8252. Approximately 275,318 shares changed hands during trading, an increase of 51% from the average daily volume of 182,465 shares. The stock had previously closed at $0.8061.

Celularity Trading Down 3.2%

The firm has a market cap of $25.19 million, a P/E ratio of -0.26 and a beta of 0.44. The company’s 50 day simple moving average is $1.13 and its 200-day simple moving average is $1.33.

Celularity (NASDAQ:CELU) last posted its earnings results on Thursday, April 30th. The company reported ($0.85) earnings per share (EPS) for the quarter. The business had revenue of $4.10 million for the quarter.

Hedge Funds Weigh In On Celularity

Several institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its stake in shares of Celularity by 106.4% in the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after purchasing an additional 11,057 shares during the period. Perennial Investment Advisors LLC bought a new position in shares of Celularity in the 3rd quarter worth approximately $28,000. Acadian Asset Management LLC bought a new position in shares of Celularity in the 1st quarter worth approximately $34,000. Geode Capital Management LLC lifted its stake in shares of Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after purchasing an additional 20,876 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares during the period. Institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.